BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Hyrnuo (Sevabertinib) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Hyrnuo (Sevabertinib)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06452277-2723@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20271028
DTEND;VALUE=DATE:20271029
SUMMARY:Hyrnuo (Sevabertinib): Phase 3 readout est. (NCT06452277)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 3\, Non-Small Cell Lung Cancer.\n
 Study: A Study to Learn More About How Well Sevabertinib Works and How Saf
 e it is Compared With Standard Treatment\, in Participants Who Have Advanc
 ed Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epiderma
 l Growth Factor Receptor 2 (HER2)\nEstimated primary completion: 28 Octobe
 r 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/sevabertinib#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0645
 2277
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05099172-2723@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20281201
DTEND;VALUE=DATE:20281202
SUMMARY:Hyrnuo (Sevabertinib): Phase 1/2 readout est. (NCT05099172)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 1/2\, Non-Small Cell Lung Cancer.
 \nStudy: First in Human Study of BAY2927088 in Participants Who Have Advan
 ced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Epid
 ermal Growth Factor Receptor (EGFR) and/or Human Epidermal Growth Factor R
 eceptor 2 (HER2)\nEstimated primary completion: 1 December 2028. This is a
  ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can m
 ove.\nDrug page: https://assetmemo.bio/drug/sevabertinib#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05099172
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06760819-2723@assetmemo.bio
DTSTAMP:20261121T005620Z
DTSTART;VALUE=DATE:20290202
DTEND;VALUE=DATE:20290203
SUMMARY:Hyrnuo (Sevabertinib): Phase 2 readout est. (NCT06760819)
DESCRIPTION:Hyrnuo (Sevabertinib)\, phase 2.\nStudy: A Study to Learn More 
 About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and
  How Safe it is in Participants Who Have a Solid Tumor With Mutations of t
 he Human Epidermal Growth Factor Receptor 2 (HER2)\nEstimated primary comp
 letion: 2 February 2029. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/sevabertinib#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT06760819
URL:https://assetmemo.bio/drug/sevabertinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
